A Phase I Study of Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease (Sr-aGvHD)
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2018
At a glance
- Drugs Neihulizumab (Primary)
- Indications Graft-versus-host disease
- Focus Pharmacokinetics
- Sponsors AbGenomics Corporation
- 22 Oct 2018 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
- 22 Oct 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Apr 2020.
- 31 Aug 2018 Biomarkers information updated